Biomarkers in Post Thrombotic Syndrome

Extracellular Matrix Alteration Clinical Trial

— BIPOSTO  

Official title:

New Biomarkers in Post Thrombotic Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02376764
• Other study ID #: ER.ALL.2014.04.A
• Status: Completed
• Phase: N/A
• First received: February 25, 2015
• Last updated: March 2, 2015
• Start date: February 2012
• Est. completion date: February 2015

Study information

• Verified date: March 2015
• Source: University of Cantanzaro
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee
• Study type: Observational

Clinical Trial Summary

This study aims to deepen the investigators knowledge of Post Thrombotic Syndrome and MMPs (and other related molecules such as TIMPS, NGAL and cytokines) to find a predictive molecular system to better classify the risk of patients to develop a PTS after a DVT episode, in order to monitorate more strictly the patients at high risk for developing this complication.

Description:

Post-thrombotic syndrome (PTS) is a problem that can develop in nearly half of all patients who experience a deep vein thrombosis (DVT) of lower limbs. PTS symptoms include chronic leg pain, swelling, redness, and skin ulcers. PTS lowers patients' quality of life after DVT, specifically with regards to physical and psychological symptoms and limitations in daily activities. Secondly, the treatment of PTS adds significantly to the cost of treating DVT. PTS also causes lost work productivity: patients with severe PTS and venous ulcers lose up to 2 work days per year Nowadays, there are no effective measures to reduces significatively PTS onset following a DVT episode.

Biomarkers can be of use in further exploring the etiology as well as in developing risk stratification tools for PTS. The relationship between PTS and specific biomarkers may help guide prevention and therapy based on a patient's individual risk profile.

Recent studies showed that MMPs play a significant role in vascular remodeling and endothelial dysfunction and they may explain a role in aneurysm formation as well as in all the clinical manifestations of venous disease (both for acute and chronic related events) but the cellular and molecular mechanisms involved in thrombus resolution and vein wall fibrosis remain undefined.

The presence of MMPs and TIMPs in acute venous occlusion model suggests that there is an important early interplay between protease and inhibitor during events that precede the development of venous disease.

This study aims to deepen the investigators knowledge of PTS and MMPs (and other related molecules such as NGAL and cytokines) to find a predictive molecular system to better classify the risk of patients to develop a PTS after a DVT episode, in order to monitorate more strictly the patients at high risk for developing this complication.

Patients will be recruited at their first episode of DVT and will be followed up according to standard protocols for DVT at 1,4,8,12,24, 36 months. At each visit blood sample will be collected from venipuncture in order to evaluate MMPs (and other related molecules) plasma levels.

These data will be related to clinical findings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 235
• Est. completion date: February 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Acute DVT of lower limbs.

• no known prior history of DVT

• availability to make follow-up appointments.

Exclusion Criteria:

• prior history of DVT

• neoplasia

• arterial aneurysms

• venous ulcers

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Extracellular Matrix Alteration
• Postphlebitic Syndrome
• Postthrombotic Syndrome
• Postthrombotic Syndrome With Ulcer of Left Lower Extremity
• Syndrome

Intervention

Procedure:
• Blood drawing (venipuncture)
Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Cantanzaro

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of plasma MMPs levels	MMPs plasma levels and other related molecules (TIMPS, NGAL and cytokines) will be evaluated during follow up.	36 months	No